Bio­gen hands De­nali $1B-plus in cash, $1B-plus in mile­stones to part­ner on late-stage Parkin­son’s drug

Bio­gen is hand­ing over more than a bil­lion dol­lars cash to part­ner with the up-and-com­ing neu­ro­sciences crew at De­nali on a new ther­a­py for Parkin­son’s. And the big biotech is ready to pile on more than a bil­lion dol­lars more in mile­stones — if the al­liance is a suc­cess.

For Bio­gen $BI­IB, the move on De­nali’s small mol­e­cule in­hibitors of LRRK2 puts them in line to col­lab­o­rate on a late-stage pro­gram for DNL151, which is sched­uled to start next year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER